Company: LIDRW
Filing Date: 2025-02-25
Form Type: S-1/A
Source: 0000947871-25-000219
Chunk: 35

Company: AEye, Inc.
Filing Date: 2025-02-25
Form: S-1/A
Chunk 35
---
 Subscription
Agreements, the form of which is included as Exhibit 10.1 to this prospectus.

Placement Units

Simultaneously with the IPO, CF III purchased an aggregate of 500,000 private
placement units at a price of $10.00 per unit (or an aggregate purchase price of $5,000). Each placement unit consists of one placement
share and one-third of one placement warrant to purchase one share of our Common Stock exercisable at $11.50. The sale of the Private
Placement Warrants was made pursuant to an exemption from registration contained in Section 4(a)(2) of the Securities Act.

The Tumim Stone Transaction

On December 8, 2021, we completed a private placement to Tumim Stone, pursuant
to which we have the right to sell to Tumim Stone up to $125 million in shares of our Common Stock, subject to certain limitations, from
time to time over the approximate 36-month period commencing on the closing date of the common stock purchase agreement dated December
8, 2021, provided that the conditions precedent to Commencement have occurred. We issued 10,088 shares of our Common Stock as commitment
shares to Tumim Stone as consideration for its irrevocable commitment to purchase our shares under the Purchase Agreement.

The securities were issued or sold by us under the Purchase Agreement in
reliance upon an exemption from the registration requirements under the Securities Act of 1933, or the Securities Act, afforded
by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. In the Purchase
Agreement, Tumim Stone represented to us, among other things, that it was an “accredited investor” (as such term is defined
in Rule 501(a) of Regulation D under the Securities Act).

The September 2022 Transaction

On September 15, 2022, the Company entered into a Securities Purchase Agreement
in connection with a transaction pursuant to which the Company issued to an institutional investor, a senior unsecured convertible promissory
note and a warrant to purchase the Company’s Common Stock. The offer, sale and issuance of the note and the warrant was made in
reliance upon the exemptions contained in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation
D promulgated thereunder. The Note Registration Rights Agreement requires the Company to prepare and